Metformin and salicylate synergistically activate liver AMPK, inhibit lipogenesis and improve insulin sensitivity

Metformin is the mainstay therapy for type 2 diabetes (T2D) and many patients also take salicylate-based drugs [i.e., aspirin (ASA)] for cardioprotection. Metformin and salicylate both increase AMP-activated protein kinase (AMPK) activity but by distinct mechanisms, with metformin altering cellular...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Biochem J
Main Authors: Ford, Rebecca J., Fullerton, Morgan D., Pinkosky, Stephen L., Day, Emily A., Scott, John W., Oakhill, Jonathan S., Bujak, Adam L., Smith, Brennan K., Crane, Justin D., Blumer, Regje M., Marcinko, Katarina, Kemp, Bruce E., Gerstein, Hertzel C., Steinberg, Gregory R.
Formato: Artigo
Idioma:Inglês
Publicado em: 2015
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5233440/
https://ncbi.nlm.nih.gov/pubmed/25742316
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1042/BJ20150125
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados